With paltusotine, we’re developing a once-daily pill for acromegaly that may replace the life-disrupting process of getting an injection every month or needing to follow a strict daily schedule for short-acting octreotide. Now in Phase 3, a once-daily oral therapy will be a welcome development for patients and could solve for a real market need. And there’s plenty more where that came from. Read on for our latest advancements and the market opportunities they hold for investment in our focused area of endocrinology pharmaceuticals.
Events
Mar 19, 2024 at 8:30 AM EDT
Mar 12, 2024 at 4:30 PM EDT
Feb 28, 2024 at 4:30 PM EST
Press Releases
May 2, 2024
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
April 11, 2024
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 19, 2024
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
Dive deeper into Crinetics, the market needs we address, our pipeline and candidate drugs, clinical trials, and more.
Investor Resources
Data Provided by Refinitiv. Minimum 15 minutes delayed.